Press Releases

Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens Toronto, Canada, August 13, 2006 -- Updated treatment guidelines issued today by the International AIDS Society-USA (IAS-USA) now include the HIV protease inhibitor

Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011 Cambridge, MA, August 3, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that three holders of its 5.75% Convertible Senior

- VX-950 Global Phase 2b Clinical Development Plan On Track -
- Collaboration with Janssen Pharmaceutica, a Johnson & Johnson Company, Adds Important Strengths
and Development Capabilities for VX-950 -

Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals

Vertex Retains all North American Rights Janssen Obtains Exclusive Rights in Europe and Other Regions Vertex to Receive $165 Million Upfront; Tiered Royalty Averaging mid-20 Percent Range Based on Successful Commercialization New Brunswick, NJ and Cambridge, MA, June 30, 2006 -- Vertex

- PROVE 1 & PROVE 2 Studies Expected to Enroll 580 Patients -

- 12 of 12 (100%) patients HCV RNA undetectable with no evidence of viral breakthrough at end of 28 days VX-950 dosing -
- 92% (11 of 12) continued to have undetectable HCV RNA through 12 weeks of follow-on therapy -

- FDA Grants Fast Track Designation to VX-770 -

GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV Research Triangle Park, NC, and Cambridge, MA, May 16, 2006 -- GlaxoSmithKline (GSK) and

- Company Updates Corporate Governance Practices -

-New data show that plasma HCV RNA levels were below limit of detection (10 IU/mL) in 8 of 8 patients continued on peg-IFN+RBV for 12 weeks-

Results to be Presented at 41st Annual Meeting of the European Association for the Study of the Liver

–– Company on Track to Achieve Clinical, Research and Corporate Objectives ––

- Vertex earns $10 million milestone payment -

Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF Cambridge, MA, March 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.

--Vertex to Advance Clinical Program; Company Expects to Initiate Combination Study of VX-702 and Methotrexate by Mid-2006--

Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference Cambridge, MA, February 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Citigroup 2006 Healthcare Conference in Washington, DC.

-Plasma HCV RNA levels are less than 10 IU/mL in 12 of 12 patients after 28 days of dosing with VX-950/peg-IFN/RBV in Phase II study-

- Clinical, Research and Financial Objectives Achieved -

Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Cambridge, MA and Bethesda, MD, January 12, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.